Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Non-Current Deffered Revenue: 2020-2024

Historic Non-Current Deffered Revenue for Beam Therapeutics (BEAM) over the last 5 years, with Dec 2024 value amounting to $33.2 million.

  • Beam Therapeutics' Non-Current Deffered Revenue fell 82.43% to $10.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.2 million, marking a year-over-year decrease of 82.43%. This contributed to the annual value of $33.2 million for FY2024, which is 69.77% down from last year.
  • Per Beam Therapeutics' latest filing, its Non-Current Deffered Revenue stood at $33.2 million for FY2024, which was down 69.77% from $109.9 million recorded in FY2023.
  • Beam Therapeutics' Non-Current Deffered Revenue's 5-year high stood at $262.3 million during FY2021, with a 5-year trough of $394,000 in FY2020.
  • Moreover, its 3-year median value for Non-Current Deffered Revenue was $109.9 million (2023), whereas its average is $115.1 million.
  • Per our database at Business Quant, Beam Therapeutics' Non-Current Deffered Revenue skyrocketed by 66,474.37% in 2021 and then tumbled by 69.77% in 2024.
  • Yearly analysis of 5 years shows Beam Therapeutics' Non-Current Deffered Revenue stood at $394,000 in 2020, then soared by 66,474.37% to $262.3 million in 2021, then fell by 22.92% to $202.2 million in 2022, then plummeted by 45.65% to $109.9 million in 2023, then slumped by 69.77% to $33.2 million in 2024.